Nuvectis Pharma, Inc.
NVCT Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$18.44
KIRA · Stoqly’s AI analyst, in plain words
- Nuvectis Pharma, Inc. lost $26.4M in fiscal 2025.
Market cap
$433M
P/E
—
Revenue
—
Net income
−$26.4M
Free cash flow
—
Operating margin
—
Nuvectis Pharma, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$26.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Nuvectis Pharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 11, 2026
- Legal name
- Nuvectis Pharma, Inc.
- CIK
- 0001875558
Nuvectis Pharma, Inc. · NVCT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$12.9M | −$19.1M | −$22.3M | −$19.0M | −$26.4M |
| Diluted EPS | −$3.02 | −$1.51 | −$1.43 | −$1.11 | −$1.32 |
| Cash | |||||
| Cash from operations | −$9.5M | −$13.6M | −$16.0M | −$12.2M | −$16.0M |
| Share count change | — | 196.6% | 22.9% | 10.0% | 27.5% |
| Debt and strength | |||||
| Cash and short-term investments | $5.7M | $20.0M | $19.1M | $18.5M | $31.6M |
| Shareholders' equity | −$11.0M | $14.2M | $12.2M | $9.7M | $18.4M |
| Current ratio | 2.4x | 3.3x | 2.7x | 2.1x | 2.4x |
| Returns and quality | |||||
| Return on equity | — | −1,188.7% | −168.5% | −173.4% | −188.0% |
| Return on tangible equity | — | −134.2% | −182.4% | −195.6% | −156.8% |
| Altman Z'' | −20.7 | −4.5 | −11.2 | −15.4 | −10.8 |
Insiders bought, 12 months
$1.3M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Nuvectis Pharma, Inc. · NVCT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $18.44 a share, the company is worth $433M.
Source: SEC EDGAR XBRL filings (CIK 0001875558). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.